A detailed history of State Street Corp transactions in Chroma Dex Corp. stock. As of the latest transaction made, State Street Corp holds 555,336 shares of CDXC stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
555,336
Previous 190,239 191.91%
Holding current value
$3.25 Million
Previous $662,000 129.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.44 - $4.32 $890,836 - $1.58 Million
365,097 Added 191.91%
555,336 $1.52 Million
Q1 2023

May 15, 2023

BUY
$1.48 - $2.19 $19,832 - $29,346
13,400 Added 7.58%
190,239 $291,000
Q3 2022

Nov 15, 2022

SELL
$1.19 - $2.06 $71,709 - $124,135
-60,260 Reduced 25.42%
176,839 $218,000
Q2 2022

Aug 15, 2022

SELL
$1.59 - $2.7 $1.11 Million - $1.88 Million
-695,427 Reduced 74.57%
237,099 $396,000
Q1 2022

May 16, 2022

BUY
$2.02 - $3.92 $73,342 - $142,327
36,308 Added 4.05%
932,526 $2.29 Million
Q4 2021

Feb 14, 2022

BUY
$3.74 - $6.7 $40,597 - $72,728
10,855 Added 1.23%
896,218 $3.35 Million
Q3 2021

Nov 15, 2021

BUY
$6.05 - $10.41 $306,856 - $527,995
50,720 Added 6.08%
885,363 $5.55 Million
Q2 2021

Aug 16, 2021

BUY
$6.66 - $10.92 $707,338 - $1.16 Million
106,207 Added 14.58%
834,643 $8.23 Million
Q1 2021

May 17, 2021

BUY
$4.59 - $18.74 $66,509 - $271,542
14,490 Added 2.03%
728,436 $6.8 Million
Q4 2020

Feb 16, 2021

SELL
$3.93 - $5.5 $45,760 - $64,042
-11,644 Reduced 1.6%
713,946 $3.43 Million
Q3 2020

Nov 10, 2020

SELL
$4.01 - $5.56 $21,621 - $29,979
-5,392 Reduced 0.74%
725,590 $2.91 Million
Q2 2020

Aug 14, 2020

BUY
$3.0 - $5.52 $97,680 - $179,731
32,560 Added 4.66%
730,982 $3.36 Million
Q1 2020

May 11, 2020

BUY
$2.54 - $4.75 $1.77 Million - $3.32 Million
698,422 New
698,422 $2.28 Million

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $401M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.